- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00669422
ChemoFx® PRO - A Post-Market Data Collection Study
ChemoFx® PRO - A Post-Market Data Collection Study Utilizing Physician Reported Outcomes
Descripción general del estudio
Estado
Descripción detallada
The traditional treatment course for new cases of many cancers is cytoreductive surgery followed by chemotherapy. Unfortunately, despite high initial response rates to treatment, the majority of patients recur. The use of ineffective chemotherapy can result in unnecessary toxicity and costs, delay of more effective treatment, and the potential for the development of cross-resistance to additional drugs. The ability to individualize therapy by providing the treating physician with ex vivo response information on a panel of drugs should aid in the selection of effective therapy for individual patients, thus resulting in improved outcomes.
ChemoFx® is a drug response marker that quantifies an individual cancer patient's probable tumor response to various chemotherapeutic and biologic agents-providing both sensitivity and resistance information. In a retrospective study, it was demonstrated that patients treated with a regimen that the ChemoFx® test said the patients' cells would be sensitive to, corresponded to a 3 times longer progression free interval.
In the PT-206 ChemoFx PRO® study, patients will be followed through treatment, until the patient progresses or a significant change in chemotherapy occurs. This data will be collected and analyzed to identify potential patient cohorts for the development of hypotheses for future sub-study analysis. Also, tumor pathology slides and excess tumor cells (if available) will be used to characterize common polymorphisms in drug metabolizing enzymes as well as other molecular markers potentially associated with tumor response.
The PT-206 ChemoFx PRO® Study seeks to enroll an estimated 3,000 patients from 150 academic and community-based physicians in the U.S. The patients will be treated with drugs and/or drug combinations based on the medical judgment of the treating physician. This study is not randomized.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- University of Alabama at Birmingham
-
Mobile, Alabama, Estados Unidos, 36688
- University Of South Alabama
-
-
California
-
San Francisco, California, Estados Unidos, 94115
- University of California San Francisco
-
Sherman Oaks, California, Estados Unidos, 91403
- Women's Cancer Center of Southern California
-
Torrance, California, Estados Unidos, 91403
- GOA Torrance Memorial
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06106
- Hartford Hospital
-
New Haven, Connecticut, Estados Unidos, 06111
- Yale University
-
-
Florida
-
Boca Raton, Florida, Estados Unidos, 33487
- South Florida Center for Gynecologic Oncology
-
Clearwater, Florida, Estados Unidos, 33756
- West Coast Gynecologic Oncology
-
Coconut Creek, Florida, Estados Unidos, 33073
- Florida Center for Gynecologic Oncology
-
Delray Beach, Florida, Estados Unidos, 33444
- Comprehensive Gynecologic Oncology
-
Fort Lauderdale, Florida, Estados Unidos, 33308
- Caruso and Gates MDs PA
-
Fort Myers, Florida, Estados Unidos, 33901
- Florida Gynecologic Oncology
-
Hollywood, Florida, Estados Unidos, 33021
- Gynecologic Oncology Associates
-
Sarasota, Florida, Estados Unidos, 34239
- Sarasota Memorial Hospital
-
South Miami, Florida, Estados Unidos, 33143
- South Miami Gynecologic Oncology Group
-
West Palm Beach, Florida, Estados Unidos, 33401
- Palm Beach Cancer Institute
-
-
Georgia
-
Riverdale, Georgia, Estados Unidos, 30274
- Southeastern Gynecologic Oncology, LLC
-
Savannah, Georgia, Estados Unidos, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96813
- The Queens' Medical Center
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Rush University
-
Evanston, Illinois, Estados Unidos, 60201
- Northshore Medical Group
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Indiana University
-
-
Louisiana
-
Covington, Louisiana, Estados Unidos, 70433
- Women's Cancer Center
-
Shreveport, Louisiana, Estados Unidos, 71101
- CHRISTUS Schumpert Health System
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21215
- Sinai Hospital
-
Silver Springs, Maryland, Estados Unidos, 20852
- Women's Health Specialists
-
-
Massachusetts
-
Worcester, Massachusetts, Estados Unidos, 01605
- UMass Memorial Hospital
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Karmanos Cancer Institute
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Health System
-
Grand Rapids, Michigan, Estados Unidos, 49546
- Gynecologic Oncology of West Michigan
-
-
Mississippi
-
Jackson, Mississippi, Estados Unidos, 39216
- Mississippi Oncology Associates
-
-
New Jersey
-
Morristown, New Jersey, Estados Unidos, 07962
- Atlantic Health Systems
-
Neptune, New Jersey, Estados Unidos, 07765
- Jersey Shore University Medical Center
-
Teaneck, New Jersey, Estados Unidos, 07066
- Gara M Sommers MD
-
Voorhees, New Jersey, Estados Unidos, 08043
- Cooper Health System
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- Women's Cancer Care Associates
-
Atlantic Beach, New York, Estados Unidos, 11509
- St. John's Episcopal Hospital
-
Bronx, New York, Estados Unidos, 10461
- Montefiore Medical Center
-
Buffalo, New York, Estados Unidos, 14263
- Roswell Park Cancer Institute
-
Manhassett, New York, Estados Unidos, 11030
- North Shore Lij Health System
-
New York, New York, Estados Unidos, 10032
- Columbia University Medical Center
-
New York, New York, Estados Unidos, 10038
- New York Downtown Hospital
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28806
- Hope: A Women's Cancer Center
-
Charlotte, North Carolina, Estados Unidos, 28204
- Blumenthal Cancer Center
-
Charlotte, North Carolina, Estados Unidos, 28233
- Presbyterian Gynecologic Oncology
-
Durham, North Carolina, Estados Unidos, 27710
- Duke University Medical Center
-
Wilmington, North Carolina, Estados Unidos, 28402
- North Hanover Regional Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45267
- University of Cincinnati
-
Columbus, Ohio, Estados Unidos, 43026
- OSU Gynecologic Oncology
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73112
- Oklahoma Gynecologic Oncology Group
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- The Western Pennsylvania Hospital
-
Pittsburgh, Pennsylvania, Estados Unidos, 15224
- Allegheny-Singer Research Institute
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02905
- Women & Infants Hospital of Rhode Island
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29403
- Medical University of South Carolina Hospital
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57105
- Sandford USD Health System
-
-
Tennessee
-
Chattanooga, Tennessee, Estados Unidos, 37403
- Chattanooga's Program in Women's Oncology
-
Chattanooga, Tennessee, Estados Unidos, 37403
- Chattanooga Gynecologic Oncology
-
Knoxville, Tennessee, Estados Unidos, 37922
- Thomas W. McDonald MD
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75251
- North Texas Gynecologic Oncology
-
Ft. Sam Houston, Texas, Estados Unidos, 78234
- Brooke Army Medical Center
-
San Antonio, Texas, Estados Unidos, 78258
- South Texas Gynecologic Oncology
-
-
Virginia
-
Annandale, Virginia, Estados Unidos, 22003
- North Virigina Pelvic Surgery Associates
-
Roanoke, Virginia, Estados Unidos, 24016
- Carilion Clinic Gynecologic Oncology
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26505
- Mohammed Ashraf MD
-
-
Wisconsin
-
West Allis, Wisconsin, Estados Unidos, 53227
- Aurora West Allis Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Approximately 3,000 patients from 150 academic and community based physicians in the United States.
Patients have a confirmed solid tumor malignancy and their tissue specimen has been submitted to Precision Therapeutics, Inc. as part of the patient's medical care
Descripción
Inclusion Criteria:
- Patient has been diagnosed with a solid tumor malignancy and their physician has received a final report for ChemoFx® after August 1, 2006
- Chemotherapy must be clinically indicated for treatment of the patient's qualifying disease
- Patient must be at least 18 years of age
- Patient must have signed an IRB approved informed consent form for the data collection study prior to entry of data into the enrollment form in the database.
Exclusion Criteria:
- Patient pathology shows benign pathology for sample submitted
- Patient is not indicated to receive chemotherapy for their disease
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
To collect physician reported outcomes after the first chemotherapy utilized following the receipt of a final report from ChemoFx® in solid tumor malignancies for the generation of hypotheses for further sub-study.
Periodo de tiempo: 24-36 Months depending on Disease Status
|
24-36 Months depending on Disease Status
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Identify possible enhancements of the predictive and prognostic capabilities of the assay through the inclusion of molecular markers.
Periodo de tiempo: 24-36 Months depending on Disease Status
|
24-36 Months depending on Disease Status
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ; American Cancer Society. Cancer statistics, 2004. CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29. doi: 10.3322/canjclin.54.1.8.
- Ness RB, Wisniewski SR, Eng H, Christopherson W. Cell viability assay for drug testing in ovarian cancer: in vitro kill versus clinical response. Anticancer Res. 2002 Mar-Apr;22(2B):1145-9.
- O'Meara AT, Sevin BU. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol. 2001 Nov;83(2):334-42. doi: 10.1006/gyno.2001.6395.
- McLeod HL, King CR, Marsh S. Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies. Clin Colorectal Cancer. 2004 Jun;4 Suppl 1:S43-7. doi: 10.3816/ccc.2004.s.007.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias Genitales Femeninas
- Enfermedades del cuello uterino
- Enfermedades uterinas
- Enfermedades del sistema endocrino
- Enfermedades Ováricas
- Enfermedades anexiales
- Trastornos gonadales
- Neoplasias de glándulas endocrinas
- Enfermedades de las trompas de Falopio
- Enfermedades vaginales
- Enfermedades Vulvares
- Neoplasias del cuello uterino
- Neoplasias Ováricas
- Neoplasias de las trompas de Falopio
- Neoplasias Endometriales
- Neoplasias Vulvares
- Neoplasias vaginales
- Neoplasias Uterinas
Otros números de identificación del estudio
- PT-206 ChemoFx® PRO Study
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de cuello uterino
-
Stanford UniversityTerminadoCirugía Cervical Posterior | Fusión cervical posterior | Laminectomía cervical posterior | Laminoplastia Cervical PosteriorEstados Unidos
-
Gazi UniversityReclutamientoRadiculopatía cervical | Dolor radicular cervical | Radiculitis cervical | Síndrome de la raíz cervicalPavo
-
Blaz BarunReclutamientoLesión por latigazo cervical de la columna cervicalCroacia
-
University of IcelandLandspitali University Hospital; Reykjavik University; Empowered HealthActivo, no reclutandoLesión por latigazo cervical de la columna cervicalIslandia
-
Valérie SchuermansReclutamientoEnfermedad del disco cervical | Fusión cervical | Fusión de columna | Espondilosis cervical | Hernia de disco cervical | Mielopatía cervical | Degeneración del disco cervical | Radiculopatía Cervical | Mielopatía Compresiva | Radiculopatía, Región Cervical | Radiculopatía; en espondilosis | Radiculopatía; en... y otras condicionesPaíses Bajos
-
Istanbul Medipol University HospitalTerminadoDolor | Radiculopatía cervical | Enfermedad del disco cervical | Hernia de disco cervical | Dolor radicular cervical | Cervical; HerniaPavo
-
NuVasiveInscripción por invitaciónRadiculopatía cervical | Enfermedad del disco cervical | Enfermedad de la columna cervical | Mielopatía cervical | Espondilosis cervical | Hernia de disco cervical | Estenosis cervicalEstados Unidos
-
University of MichiganWashington University School of Medicine; LFR InternationalTerminadoLesión de la vértebra cervical | Fractura de vértebra cervicalEstados Unidos
-
Ohio State UniversityMedtronicReclutamientoFusión cervicalEstados Unidos
-
University Hospital, Strasbourg, FranceTerminado